297 related articles for article (PubMed ID: 29091205)
1. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
2. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
3. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
7. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
Chin A; Pergam SA; Fredricks DN; Hoofnagle AN; Baker KK; Jain R
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760896
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
10. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
[TBL] [Abstract][Full Text] [Related]
13. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.
Pham AN; Bubalo JS; Lewis JS
Mycoses; 2016 Apr; 59(4):226-233. PubMed ID: 26742659
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole liquid vs tablet formulation in lung transplant recipients.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
[TBL] [Abstract][Full Text] [Related]
15. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
[TBL] [Abstract][Full Text] [Related]
16. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
17. Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.
Peterlin P; Chauvin C; Le Gouill S; Pere M; Dalichampt M; Guillaume T; Garnier A; Paré M; Le Bourgeois A; Moreau P; Chevallier P; Deslandes G; Gastinne T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133564
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
[TBL] [Abstract][Full Text] [Related]
19. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
Kim JH; Benefield RJ; Ditolla K
Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.
Welch S; Pallotta A; Weber C; Siebenaller C; Cober E; Neuner E
Mycoses; 2017 Apr; 60(4):241-243. PubMed ID: 27910211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]